Last reviewed 2026-04-23 · How we verify

R-BL-M-04 + auto-SCT

Elena N.Parovichnikova · Phase 3 active Small molecule

R-BL-M-04 + auto-SCT is a Small molecule drug developed by Elena N.Parovichnikova. It is currently in Phase 3 development for Conditioning regimen for auto-SCT.

R-BL-M-04 is a conditioning regimen for auto-SCT, which involves the use of a specific chemotherapy regimen to prepare the patient's body for a stem cell transplant.

R-BL-M-04 is a conditioning regimen for auto-SCT, which involves the use of a specific chemotherapy regimen to prepare the patient's body for a stem cell transplant. Used for Conditioning regimen for auto-SCT.

At a glance

Generic name	R-BL-M-04 + auto-SCT
Sponsor	Elena N.Parovichnikova
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

The exact mechanism of R-BL-M-04 is not well-documented, but it is believed to work by suppressing the immune system and reducing the risk of graft-versus-host disease. This is achieved through a combination of chemotherapy agents that target rapidly dividing cells, including cancer cells and immune cells.

Approved indications

Conditioning regimen for auto-SCT

Common side effects

Neutropenia
Thrombocytopenia
Anemia
Nausea and vomiting
Diarrhea

Key clinical trials

R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R-BL-M-04 + auto-SCT CI brief — competitive landscape report
R-BL-M-04 + auto-SCT updates RSS · CI watch RSS
Elena N.Parovichnikova portfolio CI

Frequently asked questions about R-BL-M-04 + auto-SCT

What is R-BL-M-04 + auto-SCT?

R-BL-M-04 + auto-SCT is a Small molecule drug developed by Elena N.Parovichnikova, indicated for Conditioning regimen for auto-SCT.

How does R-BL-M-04 + auto-SCT work?

R-BL-M-04 is a conditioning regimen for auto-SCT, which involves the use of a specific chemotherapy regimen to prepare the patient's body for a stem cell transplant.

What is R-BL-M-04 + auto-SCT used for?

R-BL-M-04 + auto-SCT is indicated for Conditioning regimen for auto-SCT.

Who makes R-BL-M-04 + auto-SCT?

R-BL-M-04 + auto-SCT is developed by Elena N.Parovichnikova (see full Elena N.Parovichnikova pipeline at /company/elena-n-parovichnikova).

What development phase is R-BL-M-04 + auto-SCT in?

R-BL-M-04 + auto-SCT is in Phase 3.

What are the side effects of R-BL-M-04 + auto-SCT?

Common side effects of R-BL-M-04 + auto-SCT include Neutropenia, Thrombocytopenia, Anemia, Nausea and vomiting, Diarrhea.

Manufacturer: Elena N.Parovichnikova — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Conditioning regimen for auto-SCT
Compare: R-BL-M-04 + auto-SCT vs similar drugs
Pricing: R-BL-M-04 + auto-SCT cost, discount & access